355 studies whose primary subject is ketamine were published in 2023, up from 261 in 2022. Newest first. Back to the ketamine overview
Psychiatry, Depression & Anxiety December 30, 2023 Eyuel Terefe
we have combined the two (ketamine and CBT) in the form of ketamine-guided psychotherapy to successfully treat a patient with SCS in an acute suicidal state.
Pakistan Journal of Medical and Health Sciences December 28, 2023 Jawad Hameed, Roheena Wadud
Introduction: Ketamine, traditionally known for its anesthetic properties, is now being explored for its rapid-acting therapeutic effects in various psychiatric and pain-related disorders. Its emerging role in managing treatment-resistant depression (TRD), chronic pain, and post-traumatic stress disorder (PTSD) is supported by recent clinical evidence. Objective: To evaluate the effectiveness...
Bioinformatics December 25, 2023 Ting Liu, K. Anton Feenstra, Zhisheng Huang et al. 8 citations
MOTIVATION: Up-to-date pathway knowledge is usually presented in scientific publications for human reading, making it difficult to utilize these resources for semantic integration and computational analysis of biological pathways. We here present an approach to mining knowledge graphs by combining manual curation with automated named entity recognition and automated relation extraction. This...
Pharmaceutics December 22, 2023 Ludivine Boudieu, Myriam Mennetrier, Pierre-Michel Llorca et al. 22 citations
Ketamine and its enantiomers represent an innovative glutamatergic agent as a treatment for individuals with treatment-resistant depression (TRD) and major depressive disorder (MDD) with suicidal ideation and behavior. Intranasal (IN) formulations could allow for quick onset of action on depressive symptoms as well as a reduction in side effects by bypassing the blood–brain barrier compared...
Brain Sciences December 22, 2023 Nicolas A. Nunez, Boney Joseph, Rakesh Kumar et al. 20 citations
Ketamine has shown rapid antidepressant and anti-suicidal effects in treatment-resistant depression (TRD) with single and serial intravenous (IV) infusions, but the effectiveness for depressive episodes of bipolar disorder is less clear. We conducted an updated systematic review and meta-analysis to appraise the current evidence on the efficacy and tolerability of ketamine/esketamine in bipolar...
Pharmaceuticals December 21, 2023 Katarina Savić Vujović, Ana Jotić, Branislava Medić et al. 32 citations
Ketamine as an old-new drug has a variety of clinical implications. In the last 30 years, ketamine has become popular for acute use in humans. Ketamine in standard doses is principally utilized for the induction and maintenance of surgical procedures. Besides its use in anesthesia and analgesia, recent studies have shown that ketamine has found a place in the treatment of asthma, epilepsy,...
Iranian Journal of Psychiatry and Behavioral Sciences December 20, 2023 Gholamreza KheirAbadi, Shirin Golkar
Background: Treatment-resistant Depression (TRD) does not respond to conventional treatments. Despite the efforts made to control depression, the outcomes are controversial and inconclusive. New strategies such as ketamine use are accompanied by promising outcomes; however, the best dosage remains a question. Objectives: The current study aimed to compare the effect of 1 and 2 mg/kg of oral...
International Journal of Molecular Sciences December 20, 2023 Adam Wojtas, Agnieszka Bysiek, Marzena Maćkowiak et al. 16 citations
The pathophysiology of depression is related to the reduced volume of the hippocampus and amygdala and hypertrophy of the nucleus accumbens. The mechanism of these changes is not well understood; however, clinical studies have shown that the administration of the fast-acting antidepressant ketamine reversed the decrease in hippocampus and amygdala volume in depressed patients, and the magnitude...
bioRxiv Preprint Server December 17, 2023 Abdelmoneim Eshra, Noa Lipstein, Stefan Hallermann 1 citation preprint
Ketamine produces rapid and sustained antidepressant effects after brief exposure to a single dose. Counterintuitively, while ketamine acts primarily as a blocker of postsynaptic N-methyl-D-aspartate receptors (NMDARs), increased signalling at glutamatergic synapses has been reported. Due to technical limitations, however, it remains unclear whether ketamine directly increases presynaptic...
Frontiers in Psychiatry December 8, 2023 Alina Wilkowska, Wiesław Jerzy Cubała 10 citations
Bipolar depression constitutes a major problem in psychiatry. It correlates with high suicidality, treatment resistance, chronicity, and poor quality of life. Registered treatment for bipolar depression is limited and insufficient. There is an urgent need for implementing new therapeutic strategies. Intranasal ketamine’s enantiomer—esketamine is a novel rapid-acting antidepressant with proven...
Biochemistry and Biophysics Reports December 8, 2023 Parisa Jahani Bahnamiri, Akbar Hajizadeh Moghaddam, Mojtaba Ranjbar et al. 3 citations
Cyanobacterium Nostoc commune has long been used to alleviate various diseases. This research examines the effects of Nostoc commune extract (NCE) against behavioral disorders, cerebral oxidative stress, and inflammatory damage in the ketamine-induced schizophrenia model. Oral NCE administration (70 and 150 mg/kg/d) is performed after intraperitoneal ketamine injection (20 mg/kg) for 14...
Translational Psychiatry December 3, 2023 Laith Alexander, Peter C. T. Hawkins, Jennifer W. Evans et al. 26 citations
Abstract Activity changes within the anterior cingulate cortex (ACC) are implicated in the antidepressant effects of ketamine, but the ACC is cytoarchitectonically and functionally heterogeneous and ketamine’s effects may be subregion specific. In the context of a double-blind randomized placebo-controlled crossover trial investigating the clinical and resting-state fMRI effects of intravenous...
Nature Communications December 2, 2023 Shi-Ge Xue, Jin-Gang He, Ling-Li Lu et al.
Ketamine produces rapid antidepressant effects at sub-anesthetic dosage through early and sustained activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), however, the exact molecular mechanism still remains unclear. Transmembrane AMPAR regulatory protein-γ8 (TARP-γ8) is identified as one of AMPAR auxiliary subunits, which controls assemblies, surface trafficking...
Psychopharmacology December 1, 2023 Megan Dutton, Adem T. Can, Jim Lagopoulos et al.
Abstract Ketamine has received considerable attention for its rapid and robust antidepressant response over the past decade. Current evidence, in clinical populations, predominantly relates to parenterally administered ketamine, which is reported to produce significant undesirable side effects, with additional concerns regarding long-term safety and abuse potential. Attempts to produce a...
British Journal of Anaesthesia December 1, 2023 Wenying Duan, Kang Peng, Hui-Min Qin et al.
BACKGROUND Delayed emergence from general anaesthesia poses a significant perioperative safety hazard. Subanaesthetic doses of ketamine not only deepen anaesthesia but also accelerate recovery from isoflurane anaesthesia; however, the mechanisms underlying this phenomenon remain elusive. Esketamine exhibits a more potent receptor affinity and fewer adverse effects than ketamine and exhibits...
Progress in Neuro-Psychopharmacology and Biological Psychiatry December 1, 2023 Li Ren
Conventional antidepressants that target monoaminergic receptors require several weeks to be efficacious. This lag represents a significant problem in the currently available treatments for serious depression. Ketamine, acting as an N-methyl-d-aspartate receptor antagonist, was shown to have rapid antidepressant-like effects, marking a significant advancement in the study of mood disorders....
Psychodynamic psychiatry December 1, 2023 John G Cottone
This case report details the treatment of a longtime psychodynamic psychotherapy patient, with a particular focus on a ketamine-assisted psychotherapy (KAP) session, and how the progress achieved during this session compares with the literature on KAP. The patient is a 54-year-old woman with a history of multiple traumas, including sexual assault and life-threatening physical injuries, as well...
Hellenic Journal of Nursing Science December 1, 2023 Angeliki Statharou, Crysodimitra Galatou, Evangelos Pergadas
Introduction: Ketamine was used for the first time in 1962 in Veterinary Medicine as an anesthetic and analgesic drug. For decades it was used as a narcotic substance, more widely known as “Special K”, i.e. a recreational drug. In recent years, the scientific community has focused on its remarkable and immediate therapeutic effect on depressed patients, who showed a remission of symptoms in a...
Psychoneuroendocrinology December 1, 2023 Edem Ekpenyong Edem, Oluwatomisn Adeyosola Oguntala, Daniel Akinwale Ikuelogbon et al. 4 citations
Ketamine is an anaesthetic known to have short but rapid-acting anti-depressant effects; however, the neurobehavioural effects of its prolonged use and its role on the oxytocin system in the gut-brain axis are largely undetermined. Female BALB/c mice were either exposed to the chronic unpredictable mild stress (CUMS) paradigm for 21 days and then treated with ketamine in four doses for 14 days...
JAMA Psychiatry December 1, 2023 Chittaranjan Andrade
This Viewpoint discusses ketamine and its new and experimentally investigated on- and off-label indications that span different medical disciplines.